GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (OTCPK:CLABF) » Definitions » Forward PE Ratio

CLABF (Core One Labs) Forward PE Ratio : 0.00 (As of Apr. 28, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Core One Labs Forward PE Ratio?

Core One Labs's Forward PE Ratio for today is 0.00.

Core One Labs's PE Ratio without NRI for today is 0.00.

Core One Labs's PE Ratio (TTM) for today is 0.00.


Core One Labs Forward PE Ratio Historical Data

The historical data trend for Core One Labs's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Forward PE Ratio Chart

Core One Labs Annual Data
Trend
Forward PE Ratio

Core One Labs Quarterly Data
Forward PE Ratio

Competitive Comparison of Core One Labs's Forward PE Ratio

For the Biotechnology subindustry, Core One Labs's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core One Labs's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Core One Labs's Forward PE Ratio falls into.


;
;

Core One Labs Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Core One Labs  (OTCPK:CLABF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Core One Labs Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Core One Labs's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs Business Description

Traded in Other Exchanges
N/A
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.

Core One Labs Headlines

From GuruFocus

Core One Labs' Akome Receives Positive Results from Bioassay Studies

By GlobeNewswire GlobeNewswire 04-02-2022